• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.

作者信息

Mitra Raman L, Greenstein Steven A, Epstein Laurence M

机构信息

Northshore University Hospital, Northwell Health, Manhasset, New York.

出版信息

HeartRhythm Case Rep. 2020 Apr 1;6(5):244-248. doi: 10.1016/j.hrcr.2020.03.016. eCollection 2020 May.

DOI:10.1016/j.hrcr.2020.03.016
PMID:32363145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7195299/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/b3659875038f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/2443c6479cc8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/bb9ac1aeebfa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/b3659875038f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/2443c6479cc8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/bb9ac1aeebfa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/182c/7244638/b3659875038f/gr3.jpg

相似文献

1
An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.一种用于管理在接受氯喹或羟氯喹联合阿奇霉素治疗的2019冠状病毒病（COVID-19）患者中QT间期延长的算法：静脉注射利多卡因的潜在益处
HeartRhythm Case Rep. 2020 Apr 1;6(5):244-248. doi: 10.1016/j.hrcr.2020.03.016. eCollection 2020 May.
2
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.与阿奇霉素联合或不联合氯喹或羟氯喹相关的QT间期延长或尖端扭转型室速的安全信号。
Res Social Adm Pharm. 2021 Feb;17(2):483-486. doi: 10.1016/j.sapharm.2020.04.016. Epub 2020 Apr 19.
3
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.QT 间期延长、尖端扭转型室性心动过速和 COVID-19 短期使用氯喹或羟氯喹导致的猝死：系统评价。
Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008. Epub 2020 May 11.
4
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.在接受羟氯喹、氯喹、阿奇霉素或洛匹那韦/利托那韦治疗的 COVID-19 患者中出现 QTc 延长：系统评价和荟萃分析。
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):694-706. doi: 10.1002/pds.5234. Epub 2021 Apr 3.
5
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.对社论《心血管疾病患者的COVID-19》的回应：使用羟氯喹或氯喹及阿奇霉素治疗COVID-19：尖端扭转型室速的潜在风险。
Arch Cardiovasc Dis. 2020 May;113(5):367-368. doi: 10.1016/j.acvd.2020.04.001. Epub 2020 Apr 15.
6
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.羟氯喹/阿奇霉素治疗与 COVID-19 住院患者的 QT 间期延长。
JACC Clin Electrophysiol. 2021 Jan;7(1):16-25. doi: 10.1016/j.jacep.2020.07.016. Epub 2020 Aug 5.
7
Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.在 COVID-19 时代，在大型医疗保健系统中安全地管理潜在的 QTc 延长治疗。
Circ Arrhythm Electrophysiol. 2020 Nov;13(11):e008937. doi: 10.1161/CIRCEP.120.008937. Epub 2020 Oct 1.
8
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.新型冠状病毒疾病药物氯喹和羟氯喹，但不是阿奇霉素和瑞德西韦，可阻断 hERG 钾通道。
J Pharmacol Exp Ther. 2021 May;377(2):265-272. doi: 10.1124/jpet.120.000484. Epub 2021 Mar 5.
9
Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.与氯喹、羟氯喹和阿奇霉素相关的尖端扭转型室性心动过速：来自 VigiBase 的个体病例安全报告的回顾性分析。
Eur J Clin Pharmacol. 2021 Oct;77(10):1513-1521. doi: 10.1007/s00228-021-03133-w. Epub 2021 May 3.
10
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.氯喹和阿奇霉素在健康志愿者中的药代动力学和心电图评估。
Clin Pharmacol Ther. 2022 Oct;112(4):824-835. doi: 10.1002/cpt.2665. Epub 2022 Jun 22.

引用本文的文献

1
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
2
Practical Application of Augmented/Mixed Reality Technologies in Surgery of Abdominal Cancer Patients.增强/混合现实技术在腹部癌症患者手术中的实际应用
J Imaging. 2022 Jun 30;8(7):183. doi: 10.3390/jimaging8070183.
3
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.

本文引用的文献

1
First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.首例 COVID-19 合并暴发性心肌炎：病例报告及启示
Infection. 2020 Oct;48(5):773-777. doi: 10.1007/s15010-020-01424-5. Epub 2020 Apr 10.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
观察性、回顾性、全面的羟氯喹相关心血管不良事件的药物警戒分析，纳入 COVID-19 患者和非 COVID-19 患者。
Int J Clin Pharm. 2022 Oct;44(5):1179-1187. doi: 10.1007/s11096-022-01457-w. Epub 2022 Jul 20.
4
The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.静脉注射利多卡因在围手术期医学中的应用：麻醉、镇痛及免疫调节方面
J Clin Med. 2022 Jun 20;11(12):3543. doi: 10.3390/jcm11123543.
5
Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.新型冠状病毒肺炎患者与非新型冠状病毒肺炎患者短期口服氯喹和羟氯喹治疗的安全性：一项系统评价
Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634.
6
Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.新型冠状病毒肺炎患者室性心律失常的患病率、结局和处理。
Card Electrophysiol Clin. 2022 Mar;14(1):11-20. doi: 10.1016/j.ccep.2021.10.002. Epub 2021 Oct 29.
7
COVID-19 and arrhythmia: An overview.新型冠状病毒肺炎与心律失常：概述。
J Cardiol. 2022 Apr;79(4):468-475. doi: 10.1016/j.jjcc.2021.11.019. Epub 2021 Dec 1.
8
QTc prolongation in patients with COVID-19: a retrospective chart review.新型冠状病毒肺炎患者的QTc间期延长：一项回顾性病历审查
Transl Clin Pharmacol. 2021 Dec;29(4):197-205. doi: 10.12793/tcp.2021.29.e20. Epub 2021 Nov 25.
9
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见：COVID-19 大流行期间心血管疾病的诊断和管理：第 2 部分——治疗途径、治疗和随访。
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343.
10
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence.利用图神经网络和协调多种证据进行 COVID-19 的药物再利用。
Sci Rep. 2021 Nov 30;11(1):23179. doi: 10.1038/s41598-021-02353-5.
氯喹和羟氯喹作为对抗新型冠状病毒肺炎的现有武器。
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
4
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
5
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures.美西律可预防常规治疗无效的获得性长QT综合征中的复发性尖端扭转型室速。
JACC Clin Electrophysiol. 2015 Aug;1(4):315-322. doi: 10.1016/j.jacep.2015.05.008. Epub 2015 Jun 22.
6
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.药物诱导的长QT综合征的晚钠电流阻滞：一项前瞻性临床试验的结果。
Clin Pharmacol Ther. 2016 Feb;99(2):214-23. doi: 10.1002/cpt.205. Epub 2015 Nov 28.
7
Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials.阿奇霉素治疗相关的心血管事件和安全性结局：随机对照试验的荟萃分析
Am Health Drug Benefits. 2014 Sep;7(6):318-28.
8
Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.阿奇霉素、心血管风险、QTc间期延长、尖端扭转型室速及监管问题：基于病例报告研究的叙述性综述
Ther Adv Infect Dis. 2013 Oct;1(5):155-65. doi: 10.1177/2049936113501816.
9
Lack of association between azithromycin and death from cardiovascular causes.阿奇霉素与心血管疾病所致死亡之间无关联。
N Engl J Med. 2014 May 15;370(20):1961-2. doi: 10.1056/NEJMc1401831.
10
Cardiovascular risks with azithromycin and other antibacterial drugs.阿奇霉素及其他抗菌药物的心血管风险。
N Engl J Med. 2013 May 2;368(18):1665-8. doi: 10.1056/NEJMp1302726.